SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Biotech zooms on the BSE

31 May 2024 Evaluate

Medicamen Biotech is currently trading at Rs. 507.90, up by 27.35 points or 5.69% from its previous closing of Rs. 480.55 on the BSE.

The scrip opened at Rs. 497.35 and has touched a high and low of Rs. 538.00 and Rs. 492.70 respectively. So far 3144 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 903.50 on 11-Aug-2023 and a 52 week low of Rs. 356.75 on 13-Mar-2024.

Last one week high and low of the scrip stood at Rs. 540.95 and Rs. 475.50 respectively. The current market cap of the company is Rs. 645.77 crore.

The promoters holding in the company stood at 43.21%, while Institutions and Non-Institutions held 1.10% and 55.69% respectively.

The Inspection Department, Division of Production & Distribution Control, National Organisation for Medicines, GREECE, has inspected the General Tablets and Liquid Orals Formulation facility of Medicamen Biotech located at Phase IV, Industrial Area, Bhiwadi from May 28, 2024 and concluded on May 30, 2024.

The inspection closed with some procedural observations which will be well responded within Stipulated time. However, the Final approval (EU GMP Certification) is expected after submission of formal response to Greece Authorities. 

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.

Medicamen Biotech Share Price

267.25 8.75 (3.38%)
20-Apr-2026 15:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 932.60
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×